ArticleJournal of cancer research and clinical oncology2014
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
Article in Journal of cancer research and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.Medicine · 2019Pooled it
- Immune-related gene signature for predicting biochemical recurrence after RP in prostate cancer subtypes.Discover oncology · 2026Article
- A comprehensive analysis of the tryptophan metabolism-related gene signature to predict the prognosis of esophageal squamous cell carcinoma based on multi-omics.Frontiers in molecular biosciences · 2025Article
- Functional Integrative Bayesian Analysis of High-dimensional Multiplatform Clinicogenomic Data.Journal of the American Statistical Association · 2024Article
- BaySyn: Bayesian Evidence Synthesis for Multi-system Multiomic Integration.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023Article
- Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer.Frontiers in cell and developmental biology · 2021Article
- Clinical protein science in translational medicine targeting malignant melanoma.Cell biology and toxicology · 2019Article
- A novel CpG island methylation panel predicts survival in lung adenocarcinomas.Oncology letters · 2019Article
- Deep learning with multimodal representation for pancancer prognosis prediction.Bioinformatics (Oxford, England) · 2019Article
- The impact of DNA methylation on the cancer proteome.PLoS computational biology · 2019Article
- Where is the limit of prostate cancer biomarker research? Systematic investigation of potential prognostic and diagnostic biomarkers.BMC urology · 2019Article
- DNA methylation profiles in cancer diagnosis and therapeutics.Clinical and experimental medicine · 2018Review
- LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Epigenetics · 2017Article
- The Predictive Value ofDisease markers · 2017Review
- Integrative modelling of tumour DNA methylation quantifies the contribution of metabolism.Nature communications · 2016Article
- DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Molecular diagnosis & therapy · 2016Review
- A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study.Oncotarget · 2016Article
- DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.PloS one · 2016Article
- Clinical utility of RASSF1A methylation in human malignancies.British journal of cancer · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo explore differential methylation of HAAO, HOXD3, LGALS3, PITX2, RASSF1 and TDRD1 as a molecular tool to predict biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa).
methodsA multiplexed nested methylation-specific PCR was applied to quantify promoter methylation of the selected markers in five cell lines, 42 benign prostatic hyperplasia (BPH) and 71 high-risk PCa tumor samples. Uni- and multivariate Cox regression models were used to assess the importance of the methylation level in predicting BCR.
resultsA PCa-specific methylation marker HAAO in combination with HOXD3 and a hypomethylation marker TDRD1 distinguished PCa samples (>90 % of tumor cells each) from BPH with a sensitivity of 0.99 and a specificity of 0.95. High methylation of PITX2, HOXD3 and RASSF1, as well as low methylation of TDRD1, appeared to be significantly associated with a higher risk for BCR (HR 3.96, 3.44, 2.80 and 2.85, correspondingly) after correcting for established risk factors. When DNA methylation was treated as a continuous variable, a two-gene model PITX2 × 0.020677 + HOXD3 × 0.0043132 proved to be the best predictor of BCR (HR 4.85) compared with the individual markers. This finding was confirmed in an independent set of 52 high-risk PCa tumor samples (HR 11.89).
conclusionsDifferential promoter methylation of HOXD3, PITX2, RASSF1 and TDRD1 emerges as an independent predictor of BCR in high-risk PCa patients. A two-gene continuous DNA methylation model "PITX2 × 0.020677 + HOXD3 × 0.0043132" is a better predictor of BCR compared with individual markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.